Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Newly Diagnosed and Relapsed Mantle Cell Lymphoma: ESMO Clinical Practice Guidelines

Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv62–iv71
Authors: M. Dreyling, E. Campo, O. Hermine, M. Jerkeman, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski and M. Ladetto

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations for first-line and relapsed disease including the leukaemic non-nodal subtype. Also covered is a summary of recent phase II/III trials investigating dose-intensified first-line therapy in mantle cell lymphoma and a list of published clinical studies investigating molecular targeted approaches for patients in the relapsed stage.

These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings